ESC 2024 - In the POPular PAUSE TAVI trial, continuation of oral anticoagulation was not non-inferior to interruption of oral anticoagulation in patients undergoing TAVI.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ESC 2024 - In the POPular PAUSE TAVI trial, continuation of oral anticoagulation was not non-inferior to interruption of oral anticoagulation in patients undergoing TAVI.
This video was recorded during the ESC Congress 2024 in London, UK.
Dirk Jan van Ginkel is a physician-researcher at St. Antonius Hospital in Nieuwegein, The Netherlands.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of POPular PAUSE TAVI
Release date: 18 September 2024
ESC 2024 - In the POPular PAUSE TAVI trial, continuation of oral anticoagulation was not non-inferior to interruption of oral anticoagulation in patients undergoing TAVI.
This video was recorded during the ESC Congress 2024 in London, UK.
Dirk Jan van Ginkel is a physician-researcher at St. Antonius Hospital in Nieuwegein, The Netherlands.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Read our summary of POPular PAUSE TAVI
Release date: 18 September 2024
Stay current with the best on medical education
